Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients-Reference-Cited by-同舟云学术

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Published:2011-09 Issue:1-2 Volume:308 Page:98-102
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Kerbrat A.,Le Page E.,Leray E.,Anani T.,Coustans M.,Desormeaux C.,Guiziou C.,Kassiotis P.,Lallement F.,Laplaud D.,Diraison P.,Rouhart F.,Sartori E.,Wardi R.,Wiertlewski S.,Edan G.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference18 articles.

1. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;Polman;N Engl J Med,2006

2. Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis;Bozic;Mult Scler,2010

3. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases;Clifford;Lancet Neurol,2010

4. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab;Hartung;Lancet Neurol,2009

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS;JAMA Neurology;2024-05-01

2. Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?;Drugs;2023-09-19

3. Cytotoxic T lymphocytes in multiple sclerosis: New targets for treatment?;Translational Neuroimmunology, Volume 8;2023

4. Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis;Journal of Neurology;2022-09-16

5. Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis;Frontiers in Neurology;2021-04-14